UnknownPhase 2NCT04971551

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Principal Investigator
Yongping Song, PhD, M.D
Henan Tumor Hospital
Intervention
Jaktinib Hydrochloride Tablets(drug)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04971551 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials